8-K: Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume

Exagen Inc. announced record total revenue of $15.5 million for Q1 2025, driven by increased average selling price and AVISE CTD test volume growth.

Summary

• Exagen Inc. reported its financial results for the quarter ended March 31, 2025.
• The company achieved record total revenue of $15.5 million in Q1 2025, compared to $14.4 million in Q1 2024.
• The increase in revenue was attributed to the expansion of the AVISE CTD trailing twelve-month average selling price (ASP) to $419, a $42 increase per test compared to Q1 2024.
• The company's gross margin was 58.9% in Q1 2025, slightly lower than the 59.6% in Q1 2024.
• Operating expenses increased to $12.488 million from $11.601 million.
• The operating loss was $(3.365) million, compared to $(3.003) million in the same period last year.
• Net loss was $(3.752) million, compared to $(3.360) million in Q1 2024.
• Adjusted EBITDA was $(2.508) million, compared to $(1.992) million in Q1 2024.
• As of March 31, 2025, Exagen had cash and cash equivalents of $11.2 million.
• Accounts receivable balance was $14.7 million.
• Combined cash, cash equivalents, and accounts receivable are projected to be approximately $28 million as of April 30, 2025.
• Exagen closed a senior secured credit facility with Perceptive Advisors on April 25, 2025, with $25 million funded at closing.
• The company expects 2025 full-year revenue of at least $65 million and anticipates being on-track to deliver positive adjusted EBITDA in the fourth quarter of 2025.

Sentiment

Score: 7

Explanation: The document presents a mixed picture. While revenue growth and ASP expansion are positive, increased operating expenses and net losses temper the overall sentiment. The secured credit facility provides financial stability, and the future outlook is optimistic, contributing to a moderately positive sentiment.

Positives

• Record total revenue of $15.5 million was achieved in Q1 2025.
• The AVISE CTD trailing twelve-month ASP increased significantly to $419.
• New SLE and RA biomarkers were launched with expected reimbursement.
• A $25 million senior secured credit facility was closed, refinancing existing debt and extending maturity.
• The company is projecting to have approximately $28 million in combined cash, cash equivalents, and accounts receivable as of April 30, 2025.
• Exagen expects 2025 full-year revenue of at least $65 million.
• The company anticipates being on-track to deliver positive adjusted EBITDA in the fourth quarter of 2025.

Negatives

• The gross margin decreased slightly from 59.6% to 58.9%.
• Operating expenses increased to $12.488 million from $11.601 million.
• The operating loss increased to $(3.365) million from $(3.003) million.
• Net loss increased to $(3.752) million from $(3.360) million.
• Adjusted EBITDA decreased to $(2.508) million from $(1.992) million.
• Cash and cash equivalents decreased to $11.2 million from $27.267 million year over year.

Risks

• Delays in reimbursement and coverage decisions from Medicare and third-party payors could impact revenue.
• Inflation and tariffs could negatively affect Exagen's margins.
• Failure to attain and maintain market acceptance of testing products could hinder commercial success.
• Inability to obtain and maintain intellectual property protection could impact the company's competitive position.
• Regulatory developments could adversely affect Exagen's business.

Future Outlook

The company expects 2025 full-year revenue of at least $65 million and anticipates being on-track to deliver positive adjusted EBITDA in the fourth quarter of 2025.

Management Comments

• The company delivered record total revenue of $15.5 million on the strength of continued ASP expansion and AVISE CTD test volume growth.
• The company enhanced AVISE CTD offering with commercial launch of new systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) biomarkers; expected reimbursement in line with initial estimates of $90 per test.

Industry Context

Exagen operates in the autoimmune diagnostics market, which is characterized by increasing demand for accurate and early diagnosis of complex autoimmune conditions. The company's focus on innovative testing solutions and patient-centered care positions it to capitalize on this growing market.

Comparison to Industry Standards

• Exagen's revenue growth of approximately 7.5% year-over-year is within the range of growth seen by other diagnostic companies in the autoimmune space.
• Companies like Myriad Genetics and Quest Diagnostics also offer diagnostic testing services, but Exagen focuses specifically on autoimmune conditions, which provides a niche market.
• The ASP of $419 for AVISE CTD is competitive within the specialized autoimmune testing market.

Stakeholder Impact

• Shareholders may react positively to the revenue growth and future outlook.
• Employees may be encouraged by the company's growth and financial stability.
• Customers (rheumatologists and patients) may benefit from the enhanced AVISE CTD offering and improved diagnostic capabilities.
• Creditors are likely to view the secured credit facility as a positive step towards financial stability.

Next Steps

• Continue commercial expansion with new sales territories.
• Focus on achieving positive adjusted EBITDA in the fourth quarter of 2025.
• Monitor reimbursement and coverage decisions from Medicare and third-party payors.
• Execute on business strategies to drive market acceptance of testing products.

Key Dates

Keywords

Exagen, Revenue, AVISE CTD, Autoimmune, Diagnostics, ASP, EBITDA, Financial Results, Biomarkers